Johnson & Johnson (J&J) has reported new outcomes from the Phase II RedirecTT-1 trial of bispecific antibodies, Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv) for relapsed/refractory multiple myeloma (r/r MM).
The data showed a high overall response rate (ORR) with durability in those who have triple-class-exposed (TCE) RRMM with true extramedullary disease (EMD).
Go deeper with GlobalData
In the trial, which enrolled 90 subjects, the investigational combo resulted in an ORR of 78.9%, with over half of the subjects achieving a complete response or better, representing a significant improvement over the average ORR of less than 40% for this patient group.
Notably, responses were also found to be high among those previously treated with B-cell maturation antigen (BCMA) CAR-T or anti-FcRH5 bispecific antibodies.
According to the company, subjects in the trial showed deep and durable responses, with 66.2% remaining in response at the data cutoff and a median follow-up of 13.4 months.
At one year, 61% of subjects were progression-free and alive, and 74.5% were alive, with median overall survival not yet reached.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe combo was found to be consistent with prior reports of them as single agents.
Subjects had the option to switch to once-a-month dosing, which might have contributed to better tolerability.
The reports of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were found to be mostly low grade.
The study’s findings were featured at the 2025 European Hematology Association Congress.
EMD represents a severe form of MM, where myeloma cells form tumours in soft tissues and organs.
Johnson & Johnson innovative medicine multiple myeloma disease area leader and vice-president Jordan Schecter said: “Patients with extramedullary myeloma, especially those who have exhausted prior therapies, need more effective treatment options.
“Our first-in-class bispecific antibodies, Talvey and Tecvayli, have transformed treatment for relapsed or refractory multiple myeloma.”
Recently, J&J reported that Tremfya decreased the symptoms and signs of active psoriatic arthritis (PsA) at 24 weeks in individuals against a placebo in the Phase IIIb APEX trial.
